Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Decreases By 96.2%

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 159,600 shares, a drop of 96.2% from the February 28th total of 4,160,000 shares. Approximately 14.9% of the shares of the company are sold short. Based on an average daily volume of 936,100 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Trading of Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP purchased a new position in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned approximately 3.33% of Hepion Pharmaceuticals at the end of the most recent quarter. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

Hepion Pharmaceuticals Stock Performance

Shares of NASDAQ HEPA traded down $0.09 during midday trading on Friday, reaching $0.52. The company’s stock had a trading volume of 706,453 shares, compared to its average volume of 263,748. The company has a market cap of $72,419.00, a P/E ratio of -0.12 and a beta of 1.62. Hepion Pharmaceuticals has a fifty-two week low of $0.51 and a fifty-two week high of $145.00. The business’s 50 day moving average price is $7.02 and its two-hundred day moving average price is $22.74.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.